Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
With clinically meaningful weight loss and cardiovascular outcomes in patients with type 2 diabetes, GLP-1RAs were further assessed in patients with overweight or obesity without type 2 diabetes in the 2021 STEP-1 trial and 2022 SURMOUNT-1 trial
F.EngelmanC
Stock solutions of lipids were prepared at 10 mg/mL in chloroform for 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn- glycero-3-phosphor-1-serine (DOPS), or dissolved in chloroform at 0.2 mg/mL for 1,2-dioleoyl-sn-glycero-3-phospho-(1-myo-inositol-3-phosphate) (PtdIns(3)P) and 1,2-dioleoyl-sn-glycero-3-phospho-(1-myo-inositol-4-phosphate) (PtdIns(4)P)
This isnt a trap, though
COAs available on request
